Lidocaine Hydrochloride Mercury Pharmaceuticals (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve and cardiac cell membranes, preventing the rapid influx of sodium that initiates an action potential. This inhibition stops nerve impulse propagation and stabilizes cardiac electrical activity, producing anesthesia and anti‑arrhythmic effects.

The appropriate dose of Lidocaine Hydrochloride is determined by the prescribing clinician based on the specific procedure, route of administration, patient weight, and clinical condition. Dosage regimens are individualized and should follow professional guidelines.

Safety data for Lidocaine Hydrochloride in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative to Lidocaine is Bupivacaine, another amide‑type local anesthetic. Bupivacaine has a longer duration of action but a higher risk of cardiotoxicity at comparable plasma levels, whereas Lidocaine offers a faster onset and a broader safety margin for short‑duration procedures.

Lidocaine Hydrochloride should be stored at ambient temperature below 25 °C, protected from direct sunlight, moisture, and freezing. Keep the product in its original packaging until use and inspect for particulate matter before administration.

The drug is supplied as a sterile injectable solution and may be given epidurally, intramuscularly, or intravenously by a qualified healthcare professional. Administration technique follows standard aseptic procedures and dosage calculations specific to the intended indication.

Serious risks include central nervous system toxicity such as seizures, severe hypotension or cardiovascular collapse, and rare anaphylactic reactions. Prompt recognition of symptoms and immediate supportive measures are essential to mitigate these events.

Patients with known hypersensitivity to amide‑type local anesthetics, those with severe heart block, uncontrolled epilepsy, or significant hepatic impairment should avoid Lidocaine Hydrochloride unless a specialist determines that benefits outweigh the risks.